|
USP24 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.97549999983949E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.02040000022386E-07 |
| Normal-vs-Stage2 |
5.72639999999458E-05 |
| Normal-vs-Stage3 |
1.54511999999052E-05 |
| Normal-vs-Stage4 |
1.185050E-04 |
| Stage1-vs-Stage2 |
4.177000E-01 |
| Stage1-vs-Stage3 |
6.688400E-01 |
| Stage1-vs-Stage4 |
8.246400E-01 |
| Stage2-vs-Stage3 |
6.636200E-01 |
| Stage2-vs-Stage4 |
6.247000E-01 |
| Stage3-vs-Stage4 |
9.218800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.90349999990214E-07 |
| Normal-vs-AfricanAmerican |
1.140100E-02 |
| Normal-vs-Asian |
4.987700E-04 |
| Caucasian-vs-AfricanAmerican |
6.053600E-01 |
| Caucasian-vs-Asian |
7.971200E-01 |
| AfricanAmerican-vs-Asian |
7.614200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.14369999979236E-07 |
| Normal-vs-Female |
3.89590000038353E-07 |
| Male-vs-Female |
7.016400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.23689999999666E-05 |
| Normal-vs-Age(41-60Yrs) |
3.43590000007055E-07 |
| Normal-vs-Age(61-80Yrs) |
3.3957999999723E-06 |
| Normal-vs-Age(81-100Yrs) |
6.959100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.863000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.602200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.398600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.598600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.432800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.769400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.914400E-01 |
| Classical-VS-Follicular |
3.189400E-04 |
| Classical-VS-Other |
4.185200E-01 |
| Classical-VS-Normal |
2.47649999999267E-05 |
| Tall-VS-Follicular |
1.953430E-01 |
| Tall-VS-Other |
7.367600E-01 |
| Tall-VS-Normal |
1.700350E-03 |
| Follicular-VS-Other |
7.036800E-01 |
| Follicular-VS-Normal |
3.72239999935076E-08 |
| Other-VS-Normal |
3.655700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.96239999595127E-08 |
| Normal-vs-N1 |
5.77859999999486E-05 |
| N0-vs-N1 |
7.768400E-01 |
|
|
